BN Business News
Add your company to Business Communicator →

Business · 30/10/2012Updated: 10/17/2026 · 1 min read

National Institutes of Health to Consider Exclusive Evaluation Option License for Medicenna Therapeutics' Ubiquitin-Based Fusion Proteins

Summary

The National Institutes of Health is seeking to grant an exclusive evaluation option license to Medicenna Therapeutics for the use of its ubiquitin-based fusion proteins, which may be used to develop human therapeutics for cancer and neurological diseases, following the expiration of a certain period.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Explore insights

Business insights →